2025 Q4 -tulosraportti
Vain PDF
21 päivää sitten
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 3 000 | - | - | ||
| 770 | - | - | ||
| 114 | - | - | ||
| 771 | - | - | ||
| 657 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·5 t sittenTHIS IS NOT ONE BIOTECH IDEA. IT IS A WHOLE STACK FOR NEXT-GENERATION MEDICINE. 🧬🔥 People are still trying to put Circio in a simple box. "They are a circular RNA company." That box is too small. The real case is that circVec is becoming the expression engine for future gene and cell therapy. An engine. And in next-generation medicine, the engine is everything. This field is no longer about swallowing pills. It's about genetic instructions. AAV. LNP. In vivo CAR-T. But in all these fields, one question is crucial: Can you get the cells to produce the right protein, in the right tissue, long enough, with a low enough dose and the least possible toxicity? This is exactly where circVec positions itself. But an engine alone doesn't win the race. You need a vehicle. Therefore, delivery is the biggest bottleneck in the industry. And this is where Circio is now building something massive. They are not locking themselves to one route. They are building three paths to the same engine: 1. The AAV track (The most mature) 🧬 Heart. Eye. CNS. The data to be presented on the main stage at ASGCT in Boston is not trivial. • Over 60x higher expression in the eye. • 40x increased expression in the heart. • 22x higher expression at 10x lower dose. • 35–200x higher RNA transcript in heart tissue. • No significant increase in AAV genome copy number, reduced liver off-targeting and cellular stress. This is not about flooding with more virus. It's about more output per biological input. Lower dose. Extreme safety-margin. 2. The LNP track (The most strategic) 🩸 Acuitas. CD4+ and CD8+ T-cells. In vivo CAR-T for oncology and autoimmune diseases. This is no longer classic gene therapy. This is therapy directly in the body. Here the test is brutal: Delivery + Expression + Function must work in symphony. If circVec can provide longer and more stable expression inside T-cells via Acuitas' LNPs, the case enters a completely different territory. 3. The Peptide track (The most flexible) 🧪 TraffikGene. Non-viral delivery. Less flashy than Acuitas in the headlines, but strategically extremely important. Why? Because it proves that the platform is delivery-agnostic. Not locked to AAV. Not locked to LNP. circVec is an expression engine that can be plugged into multiple systems. May: The Pressure Cooker 🕒 The science timeline and the finance timeline are colliding right now. The ASGCT presentations in Boston (poster May 13, oral presentation May 15) are happening simultaneously with the VWAP period for warrants (May 8–22). The world elite gets to see the data, while the market prices the capital structure. And remember: In biotech, cash is much more than money. Cash is runway. Cash is negotiating power. Cash is the ability not to sell rights too cheaply. Validation is underway 🌍 This is not just hype on Shareville. International biotech press (The Pharma Navigator, GEN, Drug Target Review) is already writing about the in vivo CAR-T angle and the Acuitas deal. At the same time, Nature Communications recently published a massive article on the function of circular RNA in complex systems. Academia validates the biology. Circio commercializes the technology. Big Pharma sees this 💼 Big Pharma doesn't ask about the daily share price. They ask: Can this reduce our dose? Extend the duration? Reduce off-target effects? Can this give us access before the competitor? It is these answers that create deals. Risk vs. Asymmetry ⚖️ Is everything proven? No. This is still preclinical biotech, and the risk is absolutely present. CAR-T PoC and partner-validated in vivo data will be critical. ASGCT is a spotlight, not a final destination. But a product case is priced on one program. A platform case is priced on optionality. Circio has several "shots on goal" that provide an extremely asymmetric case. If circVec becomes a standard engine for next-generation medicine, the upside is not linear. Then it's not about one medicine. Then it's about an IP layer. The value of de-risking is not built on one green day. It is built data point by data point. Brick by brick. We know what we own. ♟️🧱🍷
·5 t sittenThis forum is worn out with all sorts of rubbish.
·5 t sittenyes, I would recommend you to stay away from this forum:-)
·7 t sittenThis has become bearish. It is crabbing sideways downwards.
·5 t sitten · MuokattuWelcome over to the smoltek forum. There's a bull run straight up today ;)·5 t sittenit at least went straight down on that one earlier today:-) am I too late for smoltek now too perhaps, I'll join the forum there:-)
·8 t sittenStay calm until after the presentation, I think it will pay off well😊👍
·8 t sitten · MuokattuHow new a member are you? And why do you have credible experience if you are completely new? 😬🫢 those who understand how to sell and buy and acquire more shares, must surely be the winners in the end 😎
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
Vain PDF
21 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·5 t sittenTHIS IS NOT ONE BIOTECH IDEA. IT IS A WHOLE STACK FOR NEXT-GENERATION MEDICINE. 🧬🔥 People are still trying to put Circio in a simple box. "They are a circular RNA company." That box is too small. The real case is that circVec is becoming the expression engine for future gene and cell therapy. An engine. And in next-generation medicine, the engine is everything. This field is no longer about swallowing pills. It's about genetic instructions. AAV. LNP. In vivo CAR-T. But in all these fields, one question is crucial: Can you get the cells to produce the right protein, in the right tissue, long enough, with a low enough dose and the least possible toxicity? This is exactly where circVec positions itself. But an engine alone doesn't win the race. You need a vehicle. Therefore, delivery is the biggest bottleneck in the industry. And this is where Circio is now building something massive. They are not locking themselves to one route. They are building three paths to the same engine: 1. The AAV track (The most mature) 🧬 Heart. Eye. CNS. The data to be presented on the main stage at ASGCT in Boston is not trivial. • Over 60x higher expression in the eye. • 40x increased expression in the heart. • 22x higher expression at 10x lower dose. • 35–200x higher RNA transcript in heart tissue. • No significant increase in AAV genome copy number, reduced liver off-targeting and cellular stress. This is not about flooding with more virus. It's about more output per biological input. Lower dose. Extreme safety-margin. 2. The LNP track (The most strategic) 🩸 Acuitas. CD4+ and CD8+ T-cells. In vivo CAR-T for oncology and autoimmune diseases. This is no longer classic gene therapy. This is therapy directly in the body. Here the test is brutal: Delivery + Expression + Function must work in symphony. If circVec can provide longer and more stable expression inside T-cells via Acuitas' LNPs, the case enters a completely different territory. 3. The Peptide track (The most flexible) 🧪 TraffikGene. Non-viral delivery. Less flashy than Acuitas in the headlines, but strategically extremely important. Why? Because it proves that the platform is delivery-agnostic. Not locked to AAV. Not locked to LNP. circVec is an expression engine that can be plugged into multiple systems. May: The Pressure Cooker 🕒 The science timeline and the finance timeline are colliding right now. The ASGCT presentations in Boston (poster May 13, oral presentation May 15) are happening simultaneously with the VWAP period for warrants (May 8–22). The world elite gets to see the data, while the market prices the capital structure. And remember: In biotech, cash is much more than money. Cash is runway. Cash is negotiating power. Cash is the ability not to sell rights too cheaply. Validation is underway 🌍 This is not just hype on Shareville. International biotech press (The Pharma Navigator, GEN, Drug Target Review) is already writing about the in vivo CAR-T angle and the Acuitas deal. At the same time, Nature Communications recently published a massive article on the function of circular RNA in complex systems. Academia validates the biology. Circio commercializes the technology. Big Pharma sees this 💼 Big Pharma doesn't ask about the daily share price. They ask: Can this reduce our dose? Extend the duration? Reduce off-target effects? Can this give us access before the competitor? It is these answers that create deals. Risk vs. Asymmetry ⚖️ Is everything proven? No. This is still preclinical biotech, and the risk is absolutely present. CAR-T PoC and partner-validated in vivo data will be critical. ASGCT is a spotlight, not a final destination. But a product case is priced on one program. A platform case is priced on optionality. Circio has several "shots on goal" that provide an extremely asymmetric case. If circVec becomes a standard engine for next-generation medicine, the upside is not linear. Then it's not about one medicine. Then it's about an IP layer. The value of de-risking is not built on one green day. It is built data point by data point. Brick by brick. We know what we own. ♟️🧱🍷
- ·5 t sittenThis forum is worn out with all sorts of rubbish.·5 t sittenyes, I would recommend you to stay away from this forum:-)
- ·7 t sittenThis has become bearish. It is crabbing sideways downwards.·5 t sitten · MuokattuWelcome over to the smoltek forum. There's a bull run straight up today ;)·5 t sittenit at least went straight down on that one earlier today:-) am I too late for smoltek now too perhaps, I'll join the forum there:-)
- ·8 t sittenStay calm until after the presentation, I think it will pay off well😊👍·8 t sitten · MuokattuHow new a member are you? And why do you have credible experience if you are completely new? 😬🫢 those who understand how to sell and buy and acquire more shares, must surely be the winners in the end 😎
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 3 000 | - | - | ||
| 770 | - | - | ||
| 114 | - | - | ||
| 771 | - | - | ||
| 657 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
2025 Q4 -tulosraportti
Vain PDF
21 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·5 t sittenTHIS IS NOT ONE BIOTECH IDEA. IT IS A WHOLE STACK FOR NEXT-GENERATION MEDICINE. 🧬🔥 People are still trying to put Circio in a simple box. "They are a circular RNA company." That box is too small. The real case is that circVec is becoming the expression engine for future gene and cell therapy. An engine. And in next-generation medicine, the engine is everything. This field is no longer about swallowing pills. It's about genetic instructions. AAV. LNP. In vivo CAR-T. But in all these fields, one question is crucial: Can you get the cells to produce the right protein, in the right tissue, long enough, with a low enough dose and the least possible toxicity? This is exactly where circVec positions itself. But an engine alone doesn't win the race. You need a vehicle. Therefore, delivery is the biggest bottleneck in the industry. And this is where Circio is now building something massive. They are not locking themselves to one route. They are building three paths to the same engine: 1. The AAV track (The most mature) 🧬 Heart. Eye. CNS. The data to be presented on the main stage at ASGCT in Boston is not trivial. • Over 60x higher expression in the eye. • 40x increased expression in the heart. • 22x higher expression at 10x lower dose. • 35–200x higher RNA transcript in heart tissue. • No significant increase in AAV genome copy number, reduced liver off-targeting and cellular stress. This is not about flooding with more virus. It's about more output per biological input. Lower dose. Extreme safety-margin. 2. The LNP track (The most strategic) 🩸 Acuitas. CD4+ and CD8+ T-cells. In vivo CAR-T for oncology and autoimmune diseases. This is no longer classic gene therapy. This is therapy directly in the body. Here the test is brutal: Delivery + Expression + Function must work in symphony. If circVec can provide longer and more stable expression inside T-cells via Acuitas' LNPs, the case enters a completely different territory. 3. The Peptide track (The most flexible) 🧪 TraffikGene. Non-viral delivery. Less flashy than Acuitas in the headlines, but strategically extremely important. Why? Because it proves that the platform is delivery-agnostic. Not locked to AAV. Not locked to LNP. circVec is an expression engine that can be plugged into multiple systems. May: The Pressure Cooker 🕒 The science timeline and the finance timeline are colliding right now. The ASGCT presentations in Boston (poster May 13, oral presentation May 15) are happening simultaneously with the VWAP period for warrants (May 8–22). The world elite gets to see the data, while the market prices the capital structure. And remember: In biotech, cash is much more than money. Cash is runway. Cash is negotiating power. Cash is the ability not to sell rights too cheaply. Validation is underway 🌍 This is not just hype on Shareville. International biotech press (The Pharma Navigator, GEN, Drug Target Review) is already writing about the in vivo CAR-T angle and the Acuitas deal. At the same time, Nature Communications recently published a massive article on the function of circular RNA in complex systems. Academia validates the biology. Circio commercializes the technology. Big Pharma sees this 💼 Big Pharma doesn't ask about the daily share price. They ask: Can this reduce our dose? Extend the duration? Reduce off-target effects? Can this give us access before the competitor? It is these answers that create deals. Risk vs. Asymmetry ⚖️ Is everything proven? No. This is still preclinical biotech, and the risk is absolutely present. CAR-T PoC and partner-validated in vivo data will be critical. ASGCT is a spotlight, not a final destination. But a product case is priced on one program. A platform case is priced on optionality. Circio has several "shots on goal" that provide an extremely asymmetric case. If circVec becomes a standard engine for next-generation medicine, the upside is not linear. Then it's not about one medicine. Then it's about an IP layer. The value of de-risking is not built on one green day. It is built data point by data point. Brick by brick. We know what we own. ♟️🧱🍷
- ·5 t sittenThis forum is worn out with all sorts of rubbish.·5 t sittenyes, I would recommend you to stay away from this forum:-)
- ·7 t sittenThis has become bearish. It is crabbing sideways downwards.·5 t sitten · MuokattuWelcome over to the smoltek forum. There's a bull run straight up today ;)·5 t sittenit at least went straight down on that one earlier today:-) am I too late for smoltek now too perhaps, I'll join the forum there:-)
- ·8 t sittenStay calm until after the presentation, I think it will pay off well😊👍·8 t sitten · MuokattuHow new a member are you? And why do you have credible experience if you are completely new? 😬🫢 those who understand how to sell and buy and acquire more shares, must surely be the winners in the end 😎
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 3 000 | - | - | ||
| 770 | - | - | ||
| 114 | - | - | ||
| 771 | - | - | ||
| 657 | - | - |
Välittäjätilasto
Dataa ei löytynyt